122 related articles for article (PubMed ID: 24452222)
1. Heart failure and COPD: time to SHIFT?
Sanders-van Wijk S; van Empel V; Knackstedt C; Brunner-La Rocca HP
Int J Cardiol; 2014 Mar; 172(2):293-4. PubMed ID: 24452222
[No Abstract] [Full Text] [Related]
2. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study.
Tavazzi L; Swedberg K; Komajda M; Böhm M; Borer JS; Lainscak M; Robertson M; Ford I;
Int J Cardiol; 2013 Dec; 170(2):182-8. PubMed ID: 24225201
[TBL] [Abstract][Full Text] [Related]
3. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
[TBL] [Abstract][Full Text] [Related]
4. It is all about heart rate. Or is it?
Sarraf M; Francis GS
J Am Coll Cardiol; 2012 May; 59(22):1946-7. PubMed ID: 22617189
[No Abstract] [Full Text] [Related]
5. Differential impacts of achieved heart rate and achieved dose of β-blocker on clinical outcomes in heart failure with and without atrial fibrillation.
Kato N; Kinugawa K; Teruhiko I; Hironori M; Hisataka M; Toshiro I; Masaru H; Atsushi Y; Nagai R
Int J Cardiol; 2014 May; 173(2):331-3. PubMed ID: 24680244
[No Abstract] [Full Text] [Related]
6. SHIfT: Ivabradine's additional clinical benefits regardless of background beta-blocker dose.
Cardiovasc J Afr; 2012 Jul; 23(6):360. PubMed ID: 23961539
[No Abstract] [Full Text] [Related]
7. Addition of ivabradine to β-blocker improves exercise capacity in systolic heart failure patients in a prospective, open-label study.
Bagriy AE; Schukina EV; Samoilova OV; Pricolota OA; Malovichko SI; Pricolota AV; Bagriy EA
Adv Ther; 2015 Feb; 32(2):108-19. PubMed ID: 25700807
[TBL] [Abstract][Full Text] [Related]
8. Ivabradine for systolic heart failure.
Meade CM; Clements JN
JAAPA; 2018 Mar; 31(3):52-54. PubMed ID: 29470374
[TBL] [Abstract][Full Text] [Related]
9. Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial).
Böhm M; Robertson M; Ford I; Borer JS; Komajda M; Kindermann I; Maack C; Lainscak M; Swedberg K; Tavazzi L
Am J Cardiol; 2015 Dec; 116(12):1890-7. PubMed ID: 26508709
[TBL] [Abstract][Full Text] [Related]
10. The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial.
Mentz RJ; Schmidt PH; Kwasny MJ; Ambrosy AP; O'Connor CM; Konstam MA; Zannad F; Maggioni AP; Swedberg K; Gheorghiade M
J Card Fail; 2012 Jul; 18(7):515-23. PubMed ID: 22748484
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of ivabradine in patients with stable angina and comorbid chronic obstructive pulmonary disease].
Khamaeva AA; Belialov FI; Kerzina LV; Berezovskaia OV; Parshukova ED; Zakharova GIu
Kardiologiia; 2012; 52(1):15-9. PubMed ID: 22304347
[TBL] [Abstract][Full Text] [Related]
12. Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population.
Bocchi EA; Böhm M; Borer JS; Ford I; Komajda M; Swedberg K; Tavazzi L;
Cardiology; 2015; 131(4):218-24. PubMed ID: 25968495
[TBL] [Abstract][Full Text] [Related]
13. Effect of Early Treatment With Ivabradine Plus Beta-blockers on Long-term Outcomes in Patients Hospitalized With Systolic Heart Failure.
Hidalgo F; Carrasco F; Castillo JC; Anguita M
Rev Esp Cardiol (Engl Ed); 2018 Dec; 71(12):1086-1088. PubMed ID: 29373253
[No Abstract] [Full Text] [Related]
14. Optimization of heart rate lowering therapy in hospitalized patients with heart failure: Insights from the Optimize Heart Failure Care Program.
Lopatin YM; Cowie MR; Grebennikova AA; Sisakian HS; Pagava ZM; Hayrapetyan HG; Abdullaev TA; Voronkov LG; Chesnikova AI; Tseluyko VI; Tarlovskaya EI; Dadashova GM; Berkinbaev SF; Glezer MG; Koziolova NA; Rakisheva AG; Kipiani ZV; Kurlyanskaya AK
Int J Cardiol; 2018 Jun; 260():113-117. PubMed ID: 29622423
[TBL] [Abstract][Full Text] [Related]
15. Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): A randomised study.
Hidalgo FJ; Anguita M; Castillo JC; Rodríguez S; Pardo L; Durán E; Sánchez JJ; Ferreiro C; Pan M; Mesa D; Delgado M; Ruiz M
Int J Cardiol; 2016 Aug; 217():7-11. PubMed ID: 27167103
[TBL] [Abstract][Full Text] [Related]
16. Ivabradine in heart failure--no paradigm SHIFT…yet.
Teerlink JR
Lancet; 2010 Sep; 376(9744):847-9. PubMed ID: 20801501
[No Abstract] [Full Text] [Related]
17. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy.
Böhm M; Borer JS; Camm J; Ford I; Lloyd SM; Komajda M; Tavazzi L; Talajic M; Lainscak M; Reil JC; Ukena C; Swedberg K
Eur J Heart Fail; 2015 May; 17(5):518-26. PubMed ID: 25801408
[TBL] [Abstract][Full Text] [Related]
18. Heart rate and heart failure: the role of ivabradine therapy.
Reil JC; Böhm M
Curr Opin Cardiol; 2013 May; 28(3):326-31. PubMed ID: 23549235
[TBL] [Abstract][Full Text] [Related]
19. [Effect of the I(f) channel blocker ivabradine on the parameters of external respiration function in patients with chronic obstructive pulmonary disease in its stable course period].
Komlev AD; Kuziaev AI; Laskin GM; Kuzenkova VE; Kolosova MV
Ter Arkh; 2010; 82(3):23-5. PubMed ID: 20564916
[TBL] [Abstract][Full Text] [Related]
20. Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris.
Borer JS; Swedberg K; Komajda M; Ford I; Tavazzi L; Böhm M; Depre C; Wu Y; Maya J; Dominjon F
Cardiology; 2017; 136(2):138-144. PubMed ID: 27614723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
